Can BioShield Effectively Procure Medical Countermeasures that Safeguard the Nation? Hearing Before the Subcommittee on Emerging Threats, Cybersecurity and Science and Technology of the Committee on Homeland Security, House of Representatives, One Hundred Tenth Congress, First Session, April 18, 2007   [open pdf - 224KB]

From the opening statement of James Langevin: "Today the subcommittee will receive testimony regarding the BioShield program, focusing specifically on some recent difficulties within the program. Biological threats, both manmade and naturally occurring, present a real danger to the security of the United States. We must, therefore, do everything in our power to create and maintain robust tools to protect against these threats. Project BioShield can and should be an important component of our nation's defenses against such threats. This critical program is far too important to fail. Unfortunately, since its creation, BioShield has enjoyed varying levels of success, and, in recent months, there have been some fairly significant setbacks this committee is particularly concerned with. The cancellation of the $877 million anthrax vaccine contract, the largest under BioShield, after VaxGen invested $175 million of its own funds, does not bode well for the future of the program. Problems must be identified and fixed, and we must learn from any mistakes that have been made. Also of concern was the decision in March to close the request for proposals for a medical countermeasure to treat acute radiation syndrome. As this subcommittee is responsible for preparation and response for both nuclear and biological attacks, we are especially concerned about these two cancellations. However, our witnesses on both panels should not assume that this subcommittee has pre-judged these matters." Statements, letters, and materials submitted for the record include those of the following: James R. Langevin, Michael T. McCaul, Bennie G. Thompson, Donna M. Christensen, Bob Etheridge, Sheila Jackson Lee, Daniel E. Lungren, James H. Davis, Richard Hollis, Anthony Fauci, Jesse Goodman, Gerry Parker, Jeffrey Runge, and Richard Burr.

Report Number:
Serial No. 110-23
Public Domain
Retrieved From:
Government Printing Office, Congressional Hearings: http://www.gpoaccess.gov/chearings/index.html
Media Type:
Help with citations